Inside informationEnglish
Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Valneva SE
- Filed
- 10/12/2025, 17:45
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 114147_20251210